CTOs on the Move

GenomeDx Biosciences

www.genomedx.com

 
Delivering Genomic Tests that Impact Treatment Decisions GenomeDx develops and commercializes genomic tests for prostate and other urologic cancers that have a direct impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.genomedx.com
  • 1038 Homer Street
    Vancouver, BC CAN V6B 2W9
  • Phone: 888.975.4540

Executives

Name Title Contact Details
Dave Henderson
Chief Information Officer Profile

Similar Companies

LA Habilitation House

LA Habilitation House is a Long Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Greiner Bio One Inc

Greiner Bio One Inc is a Monroe, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Desert Valley Tech

Providing Cold Chain Storage Solutions to Military, EMS, and Hospital. Mobile Blood Banks, vaccines and pharmaceuticals.

Cellarity

Cellarity`s mission is to fundamentally transform the way medicines are created through the development of the first full stack digital cell. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single cell technologies, and machine learning to encode biology, model interventions, and purposefully design breakthrough medicines. By focusing on the cellular changes that underlie disease instead of a single target, Cellarity`s approach uncovers new biology and treatments and is applicable to a vast array of disease areas. The company currently has programs underway in metabolic disease, hematology, immuno-oncology, and respiratory disease. The company has raised $123 million as part of a Series B funding round with contributions from funds and accounts managed by Blackrock, The Baupost Group, Banque Pictet on behalf of their clients, and eight other investors alongside Flagship Pioneering.

Laboratory for Advanced Medicine

The Laboratory for Advanced Medicine, Inc. (LAM) is a bio-pharmaceutical company dedicated to developing revolutionary non-invasive, non-toxic technologies for disease diagnosis and intervention, with an emphasis on cancer.